Gillies MC, et al. - In this randomized clinical trial, 278 candidates were estimated to assess the influence of ranibizumab and aflibercept on best corrected visual acuity (BCVA) in treat-and-extend for neovascular age-related macular degeneration (nAMD). Investigators noted the baseline mean BCVA letter score (approximate Snellen equivalent) of 65.3 in the ranibizumab arm and 65.1 in the aflibercept arm. At 12 months, the mean change in BCVA letter scores from baseline was 7.2 for ranibizumab and 4.9 for aflibercept. They recorded 9.7, the mean number of injections from baseline to month 12 in both the arms. They concluded the equivalent impacts of aflibercept and ranibizumab for nAMD.